Zatolmilast
As of the edition of 20 October 2026, Zatolmilast is a small molecule: in active development; acts on PDE4D.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Small molecule
- Registered trials
- 11, 0 stopped early
- Disease areas
- Nervous system; Mental health; Inherited and neonatal; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PDE4D | 3',5'-cyclic-AMP phosphodiesterase 4D | Q08499 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 6 | 0 | 0 |
| Phase 2 | 4 | 3 | 1 | 0 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Tetra Discovery Partners | Lead sponsor of trials | 2015 to now |
| Shionogi | Lead sponsor of trials | 2025 to now |